Discovering potential drug-targets for personalized treatment of autoimmune disorders - what we learn from epidermolysis bullosa acquisita

References

• Wong SN, Chua SH. Spectrum of subepidermal immunobullous disorders seen at the National Skin Centre, Singapore: a 2-year review. Br J Dermatol. 2002;147(3):476–480.
   PubMed Web of Science ®Google Scholar
• Bertram F, et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7(5):434–440.
   PubMed Web of Science ®Google Scholar
• Bernard P, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. bullous diseases french study group. Arch Dermatol. 1995;131(1):48–52.
   PubMed Web of Science ®Google Scholar
• Elliott GT. Two cases of epidermolysis bullosa. J Cutan Genitourin Dis. 1895;13:10.
   Google Scholar
• Roenigk HH Jr., Ryan JG, Bergfeld WF. Epidermolysis bullosa acquisita. Report of three cases and review of all published cases. Arch Dermatol. 1971;103(1):1–10.
   PubMedGoogle Scholar
• Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381(9863):320–332.
   PubMed Web of Science ®Google Scholar
• Zumelzu C, et al. Black patients of African descent and HLA-DRB1*15:03 Frequency overrepresented in epidermolysis bullosa acquisita. J Investigative Dermatol. 2011;131(12):2386–2393.
   PubMed Web of Science ®Google Scholar
• Kim JH, Kim YH, Kim SC. Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases. Acta Derm Venereol. 2011;91(3):307–312.
   PubMed Web of Science ®Google Scholar
• Buijsrogge JJ, et al. The many faces of epidermolysis bullosa acquisita after serration pattern analysis by direct immunofluorescence microscopy. Br J Dermatol. 2011;165(1):92–98.
   PubMed Web of Science ®Google Scholar
• Ludwig RJ. Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita. ISRN Dermatol. 2013;2013:1–25.
   Google Scholar
• Paller AS, Queen LL, Woodley DT, et al. Organ-specific, phylogenetic, and ontogenetic distribution of the epidermolysis bullosa acquisita antigen. J Invest Dermatol. 1986;86(4):376–379.
   PubMed Web of Science ®Google Scholar
• Ishii N, Hamada T, Dainichi T, et al. Epidermolysis bullosa acquisita: what’s new? J Dermatol. 2010;37(3):220–230.
   PubMed Web of Science ®Google Scholar
• Chen M, Kim GH, Prakash L, et al. Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen. Autoimmunity. 2012;45(1):91–101.
   PubMed Web of Science ®Google Scholar
• Gupta R, Woodley DT, Chen M. Epidermolysis bullosa acquisita. Clin Dermatol. 2012;30(1):60–69.
   PubMed Web of Science ®Google Scholar
• Shipman AR, et al. Epidermolysis bullosa acquisita requiring multiple oesophageal dilatations. Clin Exp Dermatol. 2008;33(6):787–789.
   PubMed Web of Science ®Google Scholar
• Taniuchi K, et al. Nonscarring inflammatory epidermolysis bullosa acquisita with esophageal involvement and linear IgG deposits. J Am Acad Dermatol. 1997;36(2 Pt 2):320–322.
   PubMed Web of Science ®Google Scholar
• Hester JE, Arnstein DP, Woodley D. Laryngeal manifestations of epidermolysis bullosa acquisita. Arch Otolaryngol Head Neck Surg. 1995;121(9):1042–1044.
   PubMedGoogle Scholar
• Luke MC, et al. Mucosal morbidity in patients with epidermolysis bullosa acquisita. Arch Dermatol. 1999;135(8):954–959.
   PubMedGoogle Scholar
• Sitaru C, et al. Induction of complement-fixing autoantibodies against type VII collagen results in subepidermal blistering in mice. J Immunol. 2006;177(5):3461–3468.
   PubMed Web of Science ®Google Scholar
• Sitaru C, et al. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest. 2005;115(4):870–878.
   PubMed Web of Science ®Google Scholar
• Ishii N, et al. Autoantibody-induced intestinal inflammation and weight loss in experimental epidermolysis bullosa acquisita. J Pathol. 2011;224(2):234–244.
   PubMed Web of Science ®Google Scholar
• Reddy H, Shipman AR, Wojnarowska F. Epidermolysis bullosa acquisita and inflammatory bowel disease: a review of the literature. Clin Exp Dermatol. 2013;38(3):225–229. quiz 229-30.
   PubMed Web of Science ®Google Scholar
• Sherry-Dottridge F. Case for diagnosis: acquired epidermatolysis bullosa? Proc R Soc Med. 1962;55:409.
   PubMedGoogle Scholar
• Ray TL, et al. Epidermolysis bullosa acquisita and inflammatory bowel disease. J Am Acad Dermatol. 1982;6(2):242–252.
   PubMed Web of Science ®Google Scholar
• Labeille B, et al. Epidermolysis bullosa acquisita and Crohn’s disease. A case report with immunological and electron microscopic studies. Arch Intern Med. 1988;148(6):1457–1459.
   PubMedGoogle Scholar
• Hughes BR, Horne J. Epidermolysis bullosa acquisita and total ulcerative colitis. J R Soc Med. 1988;81(8):473–475.
   PubMed Web of Science ®Google Scholar
• Chen M, et al. The epidermolysis bullosa acquisita antigen (type VII collagen) is present in human colon and patients with crohn’s disease have autoantibodies to type VII collagen. J Invest Dermatol. 2002;118(6):1059–1064.
   PubMed Web of Science ®Google Scholar
• Oostingh GJ, et al. Subclass distribution of type VII collagen-specific autoantibodies in patients with inflammatory bowel disease. J Dermatol Sci. 2005;37(3):182–184.
   PubMed Web of Science ®Google Scholar
• Licarete E, et al. Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases. BMC Immunol. 2012;13:16.
   PubMed Web of Science ®Google Scholar
• Mihai S, et al. IgG4 autoantibodies induce dermal-epidermal separation. J Cell Mol Med. 2007;11(5):1117–1128.
   PubMed Web of Science ®Google Scholar
• Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448(7152):427–434.
   PubMed Web of Science ®Google Scholar
• Krivo JM, Miller F. Immunopathology of epidermolysis bullosa acquisita. Association with mixed cryoglobulinemia. Arch Dermatol. 1978;114(8):1218–1220.
   PubMedGoogle Scholar
• Kirtschig G, et al. Acquired subepidermal bullous diseases associated with psoriasis: a clinical, immunopathological and immunogenetic study. Br J Dermatol. 1996;135(5):738–745.
   PubMed Web of Science ®Google Scholar
• Hoshina D, et al. Epidermolysis bullosa acquisita associated with psoriasis vulgaris. Clin Exp Dermatol. 2007;32(5):516–518.
   PubMed Web of Science ®Google Scholar
• Endo Y, et al. Psoriasis vulgaris coexistent with epidermolysis bullosa acquisita. Br J Dermatol. 1997;137(5):783–786.
   PubMed Web of Science ®Google Scholar
• Woodley DT, Briggaman RA, Gammon WR. Acquired epidermolysis bullosa. A bullous disease associated with autoimmunity to type VII (anchoring fibril) collagen. Dermatol Clin. 1990;8(4):717–726.
   PubMed Web of Science ®Google Scholar
• Fine JD, Tyring S, Gammon WR. The presence of intra-lamina lucida blister formation in epidermolysis bullosa acquisita: possible role of leukocytes. J Invest Dermatol. 1989;92(1):27–32.
   PubMed Web of Science ®Google Scholar
• Delgado L, et al. Clinical and immunopathological evaluation of epidermolysis bullosa acquisita. Clin Exp Dermatol. 2011;36(1):12–18.
   PubMed Web of Science ®Google Scholar
• Nieboer C, et al. Epidermolysis bullosa acquisita. Immunofluorescence, electron microscopic and immunoelectron microscopic studies in four patients. Br J Dermatol. 1980;102(4):383–392.
   PubMed Web of Science ®Google Scholar
• Yaoita H, et al. Epidermolysis bullosa acquisita: ultrastructural and immunological studies. J Invest Dermatol. 1981;76(4):288–292.
   PubMed Web of Science ®Google Scholar
• Caux F. [Epidermolysis bullosa acquisita]. Presse Med. 2010;39(10):1081–1088.
   PubMed Web of Science ®Google Scholar
• Terra JB, et al. The n- vs u-serration is a learnable criterion to differentiate pemphigoid from epidermolysis bullosa acquisita in direct immunofluorescence serration pattern analysis. Br J Dermatol. 2013;169(1):100–105.
   PubMed Web of Science ®Google Scholar
• Saleh MA, et al. Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. J Dermatol Sci. 2011;62(3):169–175.
   PubMed Web of Science ®Google Scholar
• Marzano AV, et al. Diagnosis and disease severity assessment of epidermolysis bullosa acquisita by ELISA for anti-type VII collagen autoantibodies: an Italian multicentre study. Br J Dermatol. 2013;168(1):80–84.
   PubMed Web of Science ®Google Scholar
• Komorowski L, et al. Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. J Am Acad Dermatol. 2013;68(3):e89–e95.
   Google Scholar
• Kim JH, et al. Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions. J Eur Acad Dermatol Venereol. 2013;27(2):e224–30.
   Google Scholar
• Vorobyev A, et al. Autoantibodies to multiple epitopes on the non-collagenous-1 domain of type VII collagen induce blisters. J Invest Dermatol. 2015;135(6):1565–1573.
   Web of Science ®Google Scholar
• Engineer L, Ahmed AR. Emerging treatment for epidermolysis bullosa acquisita. J Am Acad Dermatol. 2001;44(5):818–828.
   PubMed Web of Science ®Google Scholar
• Cunningham BB, Kirchmann TT, Woodley D. Colchicine for epidermolysis bullosa acquisita. J Am Acad Dermatol. 1996;34(5 Pt 1):781–784.
   PubMed Web of Science ®Google Scholar
• Hughes AP, Callen JP. Epidermolysis bullosa acquisita responsive to dapsone therapy. J Cutan Med Surg. 2001;5(5):397–399.
   PubMed Web of Science ®Google Scholar
• Czernik A, et al. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity. 2012;45(1):111–118.
   PubMed Web of Science ®Google Scholar
• Schmidt E, et al. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol. 2006;31(4):503–508.
   PubMed Web of Science ®Google Scholar
• Cavailhes A, et al. [Successful use of combined corticosteroids and rituximab in the treatment of recalcitrant epidermolysis bullosa acquisita]. Ann Dermatol Venereol. 2009;136(11):795–799.
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Gurcan HM. Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non-responsive to conventional therapy: clinical outcome and post-treatment long-term follow-up. J Eur Acad Dermatol Venereol. 2012;26(9):1074–1083.
   PubMed Web of Science ®Google Scholar
• Han A. A practical approach to treating autoimmune bullous disorders with systemic medications. J Clin Aesthet Dermatol. 2009;2(5):19–28.
   PubMedGoogle Scholar
• Woodley DT, et al. Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita. N Engl J Med. 1984;310(16):1007–1013.
   PubMed Web of Science ®Google Scholar
• Lapiere JC, et al. Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa. J Clin Invest. 1993;92(4):1831–1839.
   PubMed Web of Science ®Google Scholar
• Gammon WR, et al. Autoantibodies to type VII collagen recognize epitopes in a fibronectin-like region of the noncollagenous (NC1) domain. J Invest Dermatol. 1993;100(5):618–622.
   PubMed Web of Science ®Google Scholar
• Chen M, et al. The cartilage matrix protein subdomain of type VII collagen is pathogenic for epidermolysis bullosa acquisita. Am J Pathol. 2007;170(6):2009–2018.
   PubMed Web of Science ®Google Scholar
• Ishii N, et al. Some epidermolysis bullosa acquisita sera react with epitopes within the triple-helical collagenous domain as indicated by immunoelectron microscopy. Br J Dermatol. 2009;160(5):1090–1093.
   PubMed Web of Science ®Google Scholar
• Ishii N, et al. Epidermolysis bullosa acquisita sera react with distinct epitopes on the NC1 and NC2 domains of type VII collagen: study using immunoblotting of domain-specific recombinant proteins and postembedding immunoelectron microscopy. Br J Dermatol. 2004;150(5):843–851.
   PubMed Web of Science ®Google Scholar
• Gammon WR, et al. Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated. J Invest Dermatol. 1988;91(3):228–232.
   PubMed Web of Science ®Google Scholar
• Ludwig RJ, et al. Generation of antibodies of distinct subclasses and specificity is linked to H2s in an active mouse model of epidermolysis bullosa acquisita. J Invest Dermatol. 2011;131(1):167–176.
   PubMed Web of Science ®Google Scholar
• Srinivas G, et al. Genome-wide mapping of gene-microbiota interactions in susceptibility to autoimmune skin blistering. Nat Commun. 2013;4:2462.
   PubMed Web of Science ®Google Scholar
• Iwata H, et al. B cells, dendritic cells, and macrophages are required to induce an autoreactive CD4 helper T cell response in experimental epidermolysis bullosa acquisita. J Immunol. 2013;191(6):2978–2988.
   PubMed Web of Science ®Google Scholar
• Kasperkiewicz M, et al. Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets. Blood. 2011;117(23):6135–6142.
   PubMed Web of Science ®Google Scholar
• Sitaru AG, et al. T cells are required for the production of blister-inducing autoantibodies in experimental epidermolysis bullosa acquisita. J Immunol. 2010;184(3):1596–1603.
   PubMed Web of Science ®Google Scholar
• Hammers CM, et al. Complement-fixing anti-type VII collagen antibodies are induced in Th1-polarized lymph nodes of epidermolysis bullosa acquisita-susceptible mice. J Immunol. 2011;187(10):5043–5050.
   PubMed Web of Science ®Google Scholar
• Samavedam UK, et al. GM-CSF modulates autoantibody production and skin blistering in experimental epidermolysis bullosa acquisita. J Immunol. 2014;192(2):559–571.
   PubMed Web of Science ®Google Scholar
• Tiburzy B, et al. Persistent autoantibody-production by intermediates between short-and long-lived plasma cells in inflamed lymph nodes of experimental epidermolysis bullosa acquisita. PLoS One. 2013;8(12):e83631.
   Google Scholar
• Kasperkiewicz M, et al. Genetic identification and functional validation of FcgammaRIV as key molecule in autoantibody-induced tissue injury. J Pathol. 2012;228(1):8–19.
   PubMed Web of Science ®Google Scholar
• Nagel A, Hertl M, Eming R. B-cell-directed therapy for inflammatory skin diseases. J Invest Dermatol. 2009;129(2):289–301.
   PubMed Web of Science ®Google Scholar
• Martin WL, et al. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell. 2001;7(4):867–877.
   PubMed Web of Science ®Google Scholar
• Kuo TT, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol. 2010;30(6):777–789.
   PubMed Web of Science ®Google Scholar
• Sesarman A, et al. Neonatal Fc receptor deficiency protects from tissue injury in experimental epidermolysis bullosa acquisita. J Mol Med (Berl). 2008;86(8):951–959.
   PubMed Web of Science ®Google Scholar
• Li N, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest. 2005;115(12):3440–3450.
   PubMed Web of Science ®Google Scholar
• Recke A, et al. Pathogenicity of IgG subclass autoantibodies to type VII collagen: induction of dermal-epidermal separation. J Autoimmun. 2010;34(4):435–444.
   PubMed Web of Science ®Google Scholar
• Mihai S, et al. The alternative pathway of complement activation is critical for blister induction in experimental epidermolysis bullosa acquisita. J Immunol. 2007;178(10):6514–6521.
   PubMed Web of Science ®Google Scholar
• Klos A, et al. The role of the anaphylatoxins in health and disease. Mol Immunol. 2009;46(14):2753–2766.
   PubMed Web of Science ®Google Scholar
• Karsten CM, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcγRIIB and dectin-1. Nat Med. 2012;18(9):1401–1406.
   PubMed Web of Science ®Google Scholar
• Sitaru C, et al. Autoantibodies to type VII collagen mediate Fcgamma-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin. Am J Pathol. 2002;161(1):301–311.
   PubMed Web of Science ®Google Scholar
• Sesarman A, et al. Binding of avian IgY to type VII collagen does not activate complement and leucocytes and fails to induce subepidermal blistering in mice. Br J Dermatol. 2008;158(3):463–471.
   PubMed Web of Science ®Google Scholar
• Iwata H, et al. Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita. J Invest Dermatol. 2015;135(3):916–919.
   PubMed Web of Science ®Google Scholar
• Collin M, Ehlers M. The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies. Exp Dermatol. 2013;22(8):511–514.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34–47.
   PubMed Web of Science ®Google Scholar
• Schulze FS, et al. Fcgamma receptors III and IV mediate tissue destruction in a novel adult mouse model of bullous pemphigoid. Am J Pathol. 2014;184(8):2185–2196.
   PubMed Web of Science ®Google Scholar
• Engineer L, et al. Epidermolysis bullosa acquisita and multiple myeloma. J Am Acad Dermatol. 2002;47(6):943–946.
   PubMed Web of Science ®Google Scholar
• Samavedam UK, et al. Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. J Autoimmun. 2013;40:74–85.
   PubMed Web of Science ®Google Scholar
• Sadeghi H, et al. Caspase-1-Independent IL-1 Release Mediates Blister formation in autoantibody-induced tissue injury through modulation of endothelial adhesion molecules. J Immunol. 2015;194(8):3656–3663.
   PubMed Web of Science ®Google Scholar
• Hirose M, Brandolini. L, Zimmer D, et al. The Allosteric CXCR1/2 Inhibitor DF2156A improves experimental epidermolysis bullosa acquisita. Genet Syndromes Gene Ther. 2013;2013(S3):9.
   Google Scholar
• Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol. 2013;13(3):159–175.
   PubMed Web of Science ®Google Scholar
• Sadeghi H, et al. The retinoid-related orphan receptor alpha is essential for the end-stage effector phase of experimental epidermolysis bullosa acquisita. J Pathol. 2015;237(1):111–122.
   PubMed Web of Science ®Google Scholar
• Chiriac MT, et al. NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage. J Pathol. 2007;212(1):56–65.
   PubMed Web of Science ®Google Scholar
• Kulkarni S, et al. PI3Kbeta plays a critical role in neutrophil activation by immune complexes. Sci Signal. 2011;4(168):ra23.
   PubMed Web of Science ®Google Scholar
• Hellberg L, et al. Methylprednisolone blocks autoantibody-induced tissue damage in experimental models of bullous pemphigoid and epidermolysis bullosa acquisita through inhibition of neutrophil activation. J Invest Dermatol. 2013;133(10):2390–2399.
   PubMed Web of Science ®Google Scholar
• Kovacs M, et al. The Src family kinases Hck, Fgr, and Lyn are critical for the generation of the in vivo inflammatory environment without a direct role in leukocyte recruitment. J Exp Med. 2014;211(10):1993–2011.
   PubMed Web of Science ®Google Scholar
• Shimanovich I, et al. Granulocyte-derived elastase and gelatinase B are required for dermal-epidermal separation induced by autoantibodies from patients with epidermolysis bullosa acquisita and bullous pemphigoid. J Pathol. 2004;204(5):519–527.
   PubMed Web of Science ®Google Scholar
• Kopecki Z, et al. Overexpression of the Flii gene increases dermal-epidermal blistering in an autoimmune ColVII mouse model of epidermolysis bullosa acquisita. J Pathol. 2011;225(3):401–413.
   PubMed Web of Science ®Google Scholar
• Kopecki Z, et al. Flightless I over-expression impairs skin barrier development, function and recovery following skin blistering. J Pathol. 2014;232(5):541–552.
   PubMed Web of Science ®Google Scholar
• Kopecki Z, Ruzehaji N, Turner C, et al. Topically applied flightless I neutralizing antibodies improve healing of blistered skin in a murine model of epidermolysis bullosa acquisita. J Investigative Dermatol. 2013;133(4):1008–1016.
   PubMed Web of Science ®Google Scholar
• Reichert JM. Marketed therapeutic antibodies compendium. MAbs. 2012;4(3):413–415.
   PubMed Web of Science ®Google Scholar
• Müller R, Dahler C, Möbs C, et al. T and B cells target identical regions of the non-collagenous domain 1 of type VII collagen in epidermolysis bullosa acquisita. Clin Immunol. 2010;135(1):99–107.
   PubMed Web of Science ®Google Scholar
• Kim YH, Duvic M, Obitz E, et al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007;109(11):4655–4662.
   PubMed Web of Science ®Google Scholar
• Stronkhorst A, Radema S, Yong SL, et al. CD4 antibody treatment in patients with active Crohn’s disease: a phase 1 dose finding study. Gut. 1997;40(3):320–327.
   PubMed Web of Science ®Google Scholar
• Van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology. 1997;49(2):351–357.
   PubMed Web of Science ®Google Scholar
• Gourgiotou K, Exadaktylou D, Aroni K, et al. Epidermolysis bullosa acquisita: treatment with intravenous immunoglobulins. J Eur Acad Dermatol Venereol. 2002;16(1):77–80.
   PubMed Web of Science ®Google Scholar
• Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol. 2007;156(1):194–196.
   PubMed Web of Science ®Google Scholar
• Saha M, Cutler T, Bhogal B, et al. Refractory epidermolysis bullosa acquisita: successful treatment with rituximab. Clin Exp Dermatol. 2009;34(8):e979–80.
   Google Scholar
• Peterson JD, Chan LS. Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007. Ther Clin Risk Manag. 2009;5(1):1–7.
   PubMedGoogle Scholar
• Solárová Z, Mojžiš J, Solár P. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review). Int J Oncol. 2015;46(3):907–926.
   PubMed Web of Science ®Google Scholar
• Collins CB, Aherne CM, Yeckes A, et al. Inhibition of N-terminal ATPase on HSP90 attenuates colitis through enhanced Treg function. Mucosal Immunol. 2013;6(5):960–971.
   PubMed Web of Science ®Google Scholar
• De Zoeten EF, Wang L, Butler K, et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol. 2011;31(10):2066–2078.
   PubMed Web of Science ®Google Scholar
• Tukaj S, Zillikens D, Kasperkiewicz M. Inhibitory effects of heat shock protein 90 blockade on proinflammatory human Th1 and Th17 cell subpopulations. Journal of Inflammation. 2014;11(1):10.
   Google Scholar
• Tukaj S, Tiburzy B, Manz R, et al. Immunomodulatory effects of heat shock protein 90 inhibition on humoral immune responses. Exp Dermatol. 2014;23(8):585–590.
   PubMed Web of Science ®Google Scholar
• Challa DK, Velmurugan R, Ober RJ, et al. FcRn: from molecular interactions to regulation of IgG pharmacokinetics and functions. Curr Top Microbiol Immunol. 2014;382:249–272.
   PubMed Web of Science ®Google Scholar
• Proetzel G, Roopenian DC. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies. Methods. 2014;65(1):148–153.
   PubMed Web of Science ®Google Scholar
• Nixon AE, Chen J, Sexton DJ, et al. Fully human monoclonal antibody inhibitors of the neonatal fc receptor reduce circulating IgG in non-human primates. Front Immunol. 2015;6:176.
   PubMed Web of Science ®Google Scholar
• Sondermann P, Jacob U. Human Fc gamma Receptor IIb Expressed in Escherichia coli Reveals IgG Binding Capability. Biol Chem. 1999;380(6):717–721.
   PubMed Web of Science ®Google Scholar
• Tillmanns S, et al., SM101, a Novel Recombinant, Soluble, Human FcγIIB Receptor, in the treatment of systemic lupus erythematosus: results of a double-blind, placebo-controlled multicenter Study. American College of Rheumatology, 2014. Meeting 2014. (Abstarct No 2833).
   Google Scholar
• Lauc G, Huffman JE, Pučić M, et al. Loci associated with N-glycosylation of human immunoglobulin G show pleiotropy with autoimmune diseases and haematological cancers. PLoS Genet. 2013;9(1):e1003225.
   PubMed Web of Science ®Google Scholar
• Ercan A, Barnes MG, Hazen M, et al. Multiple juvenile idiopathic arthritis subtypes demonstrate proinflammatory IgG glycosylation. Arthritis Rheum. 2012;64(9):3025–3033.
   PubMed Web of Science ®Google Scholar
• Collin M, Olsén A. EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG. Embo J. 2001;20(12):3046–3055.
   PubMed Web of Science ®Google Scholar
• Albert H, Collin M, Dudziak D, et al. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci U S A. 2008;105(39):15005–15009.
   PubMed Web of Science ®Google Scholar
• Van Timmeren MM, Van Der Veen BS, Stegeman CA, et al. IgG glycan hydrolysis attenuates ANCA-mediated glomerulonephritis. J Am Soc Nephrol. 2010;21(7):1103–1114.
   PubMed Web of Science ®Google Scholar
• Yang R, Otten MA, Hellmark T, et al. Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes. Nephrol Dial Transplant. 2010;25(8):2479–2486.
   PubMed Web of Science ®Google Scholar
• Allhorn M, Briceño JG, Baudino L, et al. The IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis. Blood. 2010;115(24):5080–5088.
   PubMed Web of Science ®Google Scholar
• Hirose M, Vafia K, Kalies K, et al. Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen. J Autoimmun. 2012;39(4):304–314.
   PubMed Web of Science ®Google Scholar
• Ercan A, Cui J, Chatterton DEW, et al. Aberrant IgG galactosylation precedes disease onset, correlates with disease activity, and is prevalent in autoantibodies in rheumatoid arthritis. Arthritis Rheum. 2010;62(8):2239–2248.
   PubMed Web of Science ®Google Scholar
• Pasek M, Duk M, Podbielska M, et al. Galactosylation of IgG from rheumatoid arthritis (RA) patients–changes during therapy. Glycoconj J. 2006;23(7–8):463–471.
   PubMed Web of Science ®Google Scholar
• Allhorn M, et al. Human IgG/Fc gamma R interactions are modulated by streptococcal IgG glycan hydrolysis. PLoS One. 2008;3(1):e1413.
   Google Scholar
• Nandakumar KS, et al. Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. Eur J Immunol. 2007;37(10):2973–2982.
   PubMed Web of Science ®Google Scholar
• Collin M, Shannon O, Bjorck L. IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions. Proc Natl Acad Sci U S A. 2008;105(11):4265–4270.
   PubMed Web of Science ®Google Scholar
• Citro A, et al. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. J Clin Investig. 2012;122(10):3647–3651.
   PubMed Web of Science ®Google Scholar
• Nakashima Y, et al. Drug delivery options to increase patient adherence and satisfaction in the management of rheumatoid arthritis - focus on subcutaneous tocilizumab. Drug Des Devel Ther. 2014;8:913–919.
   PubMed Web of Science ®Google Scholar
• Fleischmann RM. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis. 2006;65(8):1006–1012.
   PubMed Web of Science ®Google Scholar
• Schneider SW, et al. Prompt response of refractory Schnitzler syndrome to treatment with anakinra. J Am Acad Dermatol. 2007;56(5 Suppl):S120–122.
   Google Scholar
• Tubridy N, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology. 1999;53(3):466–472.
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375–381.
   PubMed Web of Science ®Google Scholar
• Friedrich M, et al. Pan-selectin antagonism improves psoriasis manifestation in mice and man. Arch Dermatol Res. 2006;297(8):345–351.
   PubMed Web of Science ®Google Scholar
• Bhushan M, et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br J Dermatol. 2002;146(5):824–831.
   PubMed Web of Science ®Google Scholar
• Ishida T, et al. Defucosylated Anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study. J Clin Oncol. 2012;30(8):837–842.
   PubMed Web of Science ®Google Scholar
• Ludwig RJ, Alban S, Boehncke WH. Structural requirements of heparin and related molecules to exert a multitude of anti-inflammatory activities. Mini Rev Med Chem. 2006;6(9):1009–1023.
   PubMed Web of Science ®Google Scholar
• Becker M, Franz G, Alban S. Inhibition of PMN-elastase activity by semisynthetic glucan sulfates. Thromb Haemost. 2003;89(5):915–925.
   PubMed Web of Science ®Google Scholar
• Yu X, et al. EndoS reduces the pathogenicity of anti-mCOL7 IgG through reduced binding of immune complexes to neutrophils. PLoS One. 2014;9(2):e85317.
   Google Scholar
• Kopecki Z, et al. Regulation of focal adhesions by flightless i involves inhibition of paxillin phosphorylation via a Rac1-dependent pathway. J Invest Dermatol. 2011;131(7):1450–1459.
   PubMed Web of Science ®Google Scholar
• Tukaj S, Zillikens D, Kasperkiewicz M. Heat shock protein 90: a pathophysiological factor and novel treatment target in autoimmune bullous skin diseases. Exp Dermatol. 2015;24(8):567–571.
   Web of Science ®Google Scholar
• Ishii N, et al. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin Rev Allergy Immunol. 2010;38(2–3):186–195.
   PubMed Web of Science ®Google Scholar
• Csorba K, et al. Blister-inducing antibodies target multiple epitopes on collagen VII in mice. J Cell Mol Med. 2014;18(9):1727–1739.
   PubMed Web of Science ®Google Scholar
• Woodley DT, et al. Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J Invest Dermatol. 2005;124(5):958–964.
   PubMed Web of Science ®Google Scholar
• Iwata H, et al. Animal models to investigate pathomechanisms and evaluate novel treatments for autoimmune bullous dermatoses. Curr Pharm Des. 2015;21(18):2422–2439.
   PubMed Web of Science ®Google Scholar
• Keymeulen B, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia. 2010;53(4):614–623.
   PubMed Web of Science ®Google Scholar
• Aronson R, et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care. 2014;37(10):2746–2754.
   PubMed Web of Science ®Google Scholar
• Scheerens H, et al. MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments. Arthritis Res Ther. 2011;13(5): R177.
   Google Scholar
• Acosta YY, et al. Suppression of CD4+ T lymphocyte activation in vitro and experimental encephalomyelitis in vivo by the phosphatidyl inositol 3-kinase inhibitor PIK-75. Int J Immunopathol Pharmacol. 2014;27(1):53–67.
   PubMed Web of Science ®Google Scholar
• Webster KE, et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med. 2009;206(4):751–760.
   PubMed Web of Science ®Google Scholar
• Tang Q, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008;28(5):687–697.
   PubMed Web of Science ®Google Scholar
• Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15(5):283–294.
   PubMed Web of Science ®Google Scholar
• Kalunian KC, et al. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46(12):3251–3258.
   PubMed Web of Science ®Google Scholar
• Boumpas DT, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48(3):719–727.
   PubMed Web of Science ®Google Scholar
• Shiomi A, Usui T. Pivotal roles of GM-CSF in autoimmunity and inflammation. Mediators Inflamm. 2015;2015:568543.
   PubMed Web of Science ®Google Scholar
• Edwards JC, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572–2581.
   PubMed Web of Science ®Google Scholar
• Sondermann P, et al., Novel anti-fc-gamma receptor iib antibodies and uses thereof. Google Patents. 2015.
   Google Scholar
• Hisano M, et al. Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy. Pediatr Int. 2015;57(2):313–317.
   PubMed Web of Science ®Google Scholar
• Okuda Y. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics. 2008;2(1):75–82.
   PubMedGoogle Scholar
• Boster AL, et al. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol. 2013;70(3):398–402.
   PubMed Web of Science ®Google Scholar
• Hirose M, et al. Effects of intravenous immunoglobulins on mice with experimental epidermolysis bullosa acquisita. J Invest Dermatol. 2015;135(3):768–775.
   PubMed Web of Science ®Google Scholar